Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape. Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 6 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Influenza A Virus, H7N9 Subtype Infections Overview 7 Therapeutics Development 8 Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Overview 8 Pipeline Products for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis 9 Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Development by Companies 10 Influenza A Virus, H7N9 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 11 Influenza A Virus, H7N9 Subtype Infections - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Influenza A Virus, H7N9 Subtype Infections - Products under Development by Companies 14 Influenza A Virus, H7N9 Subtype Infections - Products under Investigation by Universities/Institutes 15 Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development 16 EpiVax Inc 16 Fab'entech 17 Genentech Inc 18 GlaxoSmithKline Plc 19 Medigen Vaccine Biologics Corp 20 NanoViricides Inc 21 Visterra Inc 22 Vivaldi Biosciences Inc 23 Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 AT-501 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FBF-002 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GSK-3206640A - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 GSK-3206641A - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 influenza [strain A/H7N9] (monovalent) vaccine - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 influenza [strain A/H7N9] vaccine - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 influenza [strain A/H7N9] vaccine - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Monoclonal Antibody to Inhibit Hemagglutinin for Influenzavirus A Infections - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 NVINF-1 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 NVINF-2 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 VIS-410 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2016 8 Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H2 2016 16 Influenza A Virus, H7N9 Subtype Infections - Pipeline by Fab'entech, H2 2016 17 Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H2 2016 18 Influenza A Virus, H7N9 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 19 Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H2 2016 20 Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H2 2016 21 Influenza A Virus, H7N9 Subtype Infections - Pipeline by Visterra Inc, H2 2016 22 Influenza A Virus, H7N9 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, H2 2016 23 Assessment by Monotherapy Products, H2 2016 24 Number of Products by Stage and Target, H2 2016 26 Number of Products by Stage and Mechanism of Action, H2 2016 28 Number of Products by Stage and Route of Administration, H2 2016 30 Number of Products by Stage and Molecule Type, H2 2016 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.